Core Insights - NetraMark Holdings Inc. has announced a collaboration focused on glioblastoma (GBM) research, utilizing proprietary know-how and access to clinical and biomarker datasets from a leading U.S. academic medical center [1][5] Group 1: Collaboration and Objectives - The collaboration aims to apply NetraAI, the company's explainable AI platform, to identify patient subgroups for developing a therapeutic decision support tool for future GBM trials [2] - Specific objectives include generating insights from longitudinal cerebrospinal fluid (CSF) proteomic datasets and creating NetraPersonas to optimize trial enrichment strategies [4][5] Group 2: Glioblastoma Challenges - Glioblastoma is characterized by a median survival of just 15 months, with less than 7% of patients surviving beyond five years, and clinical trials have a failure rate exceeding 90% due to heterogeneous patient populations and limited predictive biomarkers [3] Group 3: Data Utilization and Analysis - The academic partner will provide expanded longitudinal glioblastoma proteomic datasets generated on the SomaLogic platform, which will be analyzed to identify molecular markers and understand treatment impacts [5][7] - NetraAI's unique focus mechanisms allow for the separation of small datasets into explainable and unexplainable subsets, enhancing the potential for accurate insights and reducing the risk of overfitting [6][8]

Core Viewpoint - NetraMark Holdings Inc. has signed a contract with Asklepion Pharmaceuticals to utilize its NetraAI platform for analyzing data from a pivotal Phase III pediatric clinical trial focused on intravenous L-citrulline for preventing acute lung injury in children undergoing cardiopulmonary bypass surgery for congenital heart defects [1][2]. Group 1: Company Overview - NetraMark is a leader in developing Generative Artificial Intelligence (Gen AI) and Machine Learning (ML) solutions specifically for the pharmaceutical industry [5]. - The company's technology employs a novel topology-based algorithm that can parse patient data into related subsets, allowing for accurate disease segmentation and patient classification regarding drug sensitivity and treatment efficacy [5]. Group 2: Partnership Details - The agreement with Asklepion aims to enhance the ability to demonstrate the benefits of L-citrulline in specific patient subgroups through the application of NetraAI's advanced AI technology [2][3]. - NetraMark's analysis will focus on identifying responder personas, which are subpopulations of patients most likely to benefit from the treatment, thereby informing future study designs for L-citrulline development [4]. Group 3: Strategic Importance - Asklepion's engagement with NetraMark reflects a commitment to innovation in trial design, aiming to uncover meaningful insights that can optimize patient selection and improve study outcomes [4]. - The integration of NetraAI's explainable AI analytics into Asklepion's late-phase study is expected to sharpen the understanding of L-citrulline and accelerate the development of safer, more effective treatments for children [4].

TORONTO, July 31, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the “Company” or “NetraMark”) (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials is pleased to announce that its Chief Executive Officer, George Achilleos, will be attending the 45th Annual Growth Conference hosted by Canaccord Genuity, taking place August 12–14, 2025, in Boston, Massachusetts. This event brings together innovative and disruptive growth companies across mu ...

Core Insights - NetraMark Holdings Inc. is participating in the 45th Annual Growth Conference hosted by Canaccord Genuity from August 12-14, 2025, in Boston, Massachusetts, where CEO George Achilleos will engage with institutional investors and strategic partners [1][2][4] Company Overview - NetraMark is focused on transforming clinical development through its AI platform, NetraAI, which extracts clinically relevant insights from complex datasets to identify patient subpopulations, mitigate placebo effects, and improve patient selection strategies [3][5] - The company's technology allows for the segmentation of diseases and classification of patients based on their sensitivity to drugs and treatment efficacy, utilizing a novel topology-based algorithm [5] Conference Participation - The conference serves as a networking venue for innovative growth companies and institutional investors, providing opportunities for strategic collaboration and showcasing new technology platforms [2] - George Achilleos will be available for one-on-one meetings to discuss the application of NetraMark's AI platform across various therapeutic areas [4]

TORONTO, July 28, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company transforming clinical trials and AlgoTherapeutix SAS ("AlgoTx"), a clinical-stage biotechnology company developing first-in-class therapies for chemotherapy-induced peripheral neuropathy (CIPN) today announced they have entered into an agreement. Under this agreement, NetraMark will deploy its NetraAI platform to analyze ...

TORONTO, June 23, 2025 (GLOBE NEWSWIRE) -- NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier artificial intelligence (AI) company that is transforming clinical trials has released a new preprint on arXiv demonstrating that its flagship AI platform, NetraAI, has substantially outperformed leading large language models, DeepSeek and ChatGPT. NetraAI also outperformed traditional machine learning techniques in identifying clinically meaningful patient ...

Core Insights - NetraMark Holdings Inc. is focused on leveraging AI solutions to enhance clinical trial design in the pharmaceutical industry, as highlighted by a new publication led by founder Dr. Joseph Geraci [1][2][6] - The publication discusses the integration of AI/ML in clinical trials, emphasizing the need for alignment with Good Clinical Practice (GCP) [2][4] - The collaborative effort includes contributions from various regulatory and pharmaceutical organizations, showcasing a broad consensus on the potential of AI/ML in improving clinical trial outcomes [3][4] Group 1: Publication Overview - The manuscript titled "Current Opportunities for the Integration and Use of AI/ML in Clinical Trials: Good Clinical Practice Perspectives" is now available in the Journal of the Society for Clinical Data Management [2] - It outlines ideal conditions for AI applications in clinical trials and stresses the importance of compliance, transparency, and patient safety [2][4] - The publication identifies seven real-world use cases where AI can enhance clinical trial effectiveness [4] Group 2: Challenges and Ethical Considerations - The manuscript addresses challenges and ethical considerations in adopting AI/ML in clinical trials, including data quality monitoring and patient stratification [4][5] - Key challenges include data attributability in wearable device data and the need for robust privacy controls [5] - Ethical considerations focus on ensuring AI is lawful, ethical, and socially robust, with an emphasis on explainability and auditability [5] Group 3: Company Commitment and Future Directions - NetraMark is committed to collaborating with sponsors to maximize the benefits of AI/ML in clinical trials, aiming to set industry standards for ethical compliance [6] - The company utilizes a novel topology-based algorithm to analyze patient data, enabling effective segmentation and classification for clinical trials [7] - NetraMark's approach allows for the use of smaller datasets while maintaining accuracy in disease classification and treatment efficacy [7]